Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Coverage · Pharmacy · Oncology, Pharmacy, Radiation OncologyMedium impact

MA08.186, Penpulimab-kcqx

Effective date
Dec 29, 2025
Identified
Jun 19, 2026

Summary

Independence Blue Cross published MA08.186b effective 12/29/2025, establishing new coverage criteria for penpulimab-kcqx (an immunotherapy drug) across multiple cancer types including anal carcinoma, appendiceal cancers, and nasopharyngeal carcinoma. This is a new pharmacy policy requiring billing teams to verify medical necessity criteria are met before processing claims, using unclassified drug codes C9399 or J3590.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 6 steps
01By 12/29/2025: Billing team must implement coverage verification process for all penpulimab-kcqx claims submitted to Independence Blue Cross Medicare Advantage members.
02Before processing claims, verify: (1) diagnosis matches covered indications (anal carcinoma, appendiceal cancer, or nasopharyngeal carcinoma); (2) clinical criteria are met per policy (e.g., ECOG performance status, prior treatment history, staging requirements); (3) use correct HCPCS codes (C9399 or J3590) on all claims.
03Update billing system edits to flag penpulimab-kcqx claims for manual review against MA08.186b criteria.
04Coordinate with clinical staff to ensure documentation supports medical necessity.
05Claims submitted without verification of coverage criteria will be denied.
06Obtain prior authorization from IBX if required by member's plan documents.

Codes mentioned

C9399J3590C11.0C11.1C11.2C11.3C11.8C11.9C14.0C14.2C17.0C17.1C17.2C17.3

Original notice

MA08.186, Penpulimab-kcqx
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
08.02.42b, Penpulimab-kcqxLowEffective Oct 1, 2026 · PharmacyMA08.186a, Penpulimab-kcqxMediumEffective Jun 1, 2026 · Pharmacy08.02.42, Penpulimab-kcqxMediumEffective Dec 29, 2025 · PharmacyMA08.173b, Tislelizumab-jsgr (Tevimbra®)MediumEffective Oct 1, 2026 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyPharmacyRadiation OncologyCode C9399Code J3590Code C11.0Code C11.1Code C11.2Code C11.3Code C11.8Code C11.9Code C14.0Code C14.2Code C17.0Code C17.1Code C17.2Code C17.3

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account